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We have previously shown that the MED-1,2 divergent GATA factors act apparently zygotically to specify the fates of the MS (mesoderm) and
E (endoderm) sister cells, born at the 7-cell stage of C. elegans embryogenesis. In the E cell, MED-1,2 activate transcription of the endoderm-
promoting end-1 and end-3 genes. We demonstrate by in situ hybridization that med transcripts accumulate both in the EMS cell and in the
maternal germline in a SKN-1-dependent manner. Removal of zygotic med function alone results in a weakly impenetrant loss of endoderm.
However, med-1,2(−) embryos made by mothers in which germline med transcripts have been abrogated by transgene cosuppression fail to make
endoderm 50% of the time, similar to the phenotype seen by RNAi. We also find that reduction of Med or End activity results in aberrant numbers
of intestinal cells in embryos that make endoderm. We further show that regulation of the paralogous end-1 and end-3 genes consists of both
shared and distinct inputs, and that END-3 activates end-1 expression. Our data thus reveal three new properties of C. elegans endoderm
specification: both maternal and zygotic activities of the med genes act to specify endoderm, defects in endoderm specification also result in
defects in gut cell number, and activation of the paralogous end-1 and end-3 genes differs qualitatively in the relative contributions of their
upstream regulators.
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Embryos have evolved strategies to convert the information
encoded in their genomes into a functional organism that
resembles its parents. Fundamental among these is the correct
spatiotemporal deployment of embryonic genes. Their differ-
ential activation is an otherwise unseen indication that
qualitative differences exist among cells that display a relatively
homogeneous appearance. In the nematode, C. elegans, a
network of maternal and zygotic genes acts to assign identities
to cells very early in development.
One such gene regulatory network is that which specifies the
descendants of the 4-cell-stage blastomere EMS, which divides
to produce the founder cells, MS and E, at the 7-cell stage. EMS⁎ Corresponding author. Fax: +1 951 827 4286.
E-mail address: mmaduro@citrus.ucr.edu (M.F. Maduro).
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will clonally generate the entire endoderm (intestine or gut),
while MS makes primarily mesodermal cell types, including
body muscle and the posterior half of the pharynx (Sulston et
al., 1983). Specification of MS and E is thought to occur
through the sequential activation of a cascade of genes that
starts with the maternal factor SKN-1, and proceeds through the
activation of the nearly identical paralogous genes med-1 and
med-2 in the EMS cell (Maduro et al., 2002). In turn, MED-
1,2 activate the endoderm-specifying genes end-1,3 in E, and
are prevented from doing so in MS by the repressive activity of
the TCF/LEF homolog POP-1 (Broitman-Maduro et al., 2005;
Lin et al., 1995; Maduro et al., 2002). In the E cell, POP-1 is
converted into an endoderm activator through the action of the
Wnt/MAPK/Src pathway, transduced from a cell–cell interac-
tion that occurs when EMS contacts its neighbor, P2 (Goldstein,
1992; Lo et al., 2004; Maduro et al., 2005b; Maduro and
Rothman, 2002; Rocheleau et al., 1997, 1999; Shetty et al., 2005;
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primarily by activating the T-box gene tbx-35 (Broitman-Maduro
et al., 2006).
Specification of the E fate results from a surprising number of
parallel activities that converge on the activation of end-1 and end-
3: SKN-1, MED-1,2, Wnt-modified POP-1, and the Caudal
homolog PAL-1 all contribute to E specification (Maduro et al.,
2005b; Shetty et al., 2005). Therefore, while descendants of MS
are absent in all embryos lacking skn-1 or med-1,2 function, a
significant fraction of these (∼30% of skn-1(−) embryos, and
∼50% of med-1,2(−) embryos) still make endoderm (Bowerman
et al., 1992; Coroian et al., 2005; Maduro et al., 2001).
A recent study has challenged the notion that the MEDs are
substantially required for endoderm specification (Goszczynski
and McGhee, 2005). In that study, chromosomal med-1,2(−)
embryos segregated from a mother carrying med-2(+) were
found to specify endoderm between 80% and 97% of the time,
contrasting with the 50% we have observed (Coroian et al.,
2005; Maduro et al., 2001). While the most obvious explanation
would be that a maternal contribution of the meds accounts for
the difference, Goszczynski and McGhee reported that they
could find no evidence for maternal med activity. Here we use
in situ hybridization to show that the med genes are indeed
expressed both maternally and zygotically in C. elegans and
in the closely related species C. briggsae. Furthermore, med-
1,2(−) embryos lacking both the maternal and zygotic
components of med activity display a strong endoderm
phenotype. We also find that med-1,2(−) embryos that make
endoderm contain an abnormal number of gut cells, and that this
phenotype is also a characteristic of skn-1 and end-3 mutants.
We extend earlier observations suggesting that end-3 is
expressed earlier than end-1 in the E lineage (Baugh et al.,
2003) and show that END-3 activates end-1 expression.
Our results validate our original model for C. elegans
endoderm specification through med-1,2 and add additional
levels of complexity to our understanding of this unexpectedly
complex gene regulatory network. These results also suggest
that at least some embryonic specification genes are expressed
in the C. elegans germ line, working against mechanisms that
maintain germ cell totipotency.Materials and methods
C. elegans strains and genetics
Genetic manipulation and crosses were performed as described (Brenner,
1974). The following mutations, rearrangements or transgenes were used: LGX:
lon-2(e678), and med-1(ok804). LGIII: dpy-17(e499), sDf127, med-2(cx9744),
unc-36(e251), and unc-32(e189). LGIV: skn-1(zu67). LGV: dpy-11(e224),
end-1(ok558), end-1(ox134), and end-3(ok1448). Free duplications: sDp3(III;f )
[complements dpy-17, sDf127, and unc-36] and irDp1(III;f ) [complements
dpy-17, sDf127, unc-36, unc-32, and med-1]. Translocation: nT1[unc-?(n754)
let-?](IV;V). Integrated transgenes: wIs84 X [elt-2::GFP]; irIs25 V [elt-2::GFP];
cuIs2 V [ceh-22::GFP]. Unmapped integrants: irIs21, irIs22, irIs23 [elt-2::
YFP]; qtIs12 [pal-1::YFP]. The ok558, ok1448, ok804, and cx9744 lesions are
described in Wormbase (http://www.wormbase.org, release WS160; cx9744 is
also known as cxTi9744).
The free duplication irDp1 was constructed as follows. BC4638 [dpy-17
sDf127 unc-32; sDp3] hermaphrodites were made transgenic for an array(irEx14) carrying an unc-119::NLS::YFP::lacZ fusion (pMM531), the unc-32-
rescuing plasmid pAIE5 (Pujol et al., 2001), and the med-1(+) plasmid
pMM277. Expression of the unc-119 reporter can be followed at all stages
beginning in mid-embryogenesis (Maduro and Pilgrim, 1995). The balancer
irDp1 was recovered as spontaneous integrant of irEx14 that had become
linked to sDp3, allowing irDp1(+) animals to be identified by unc-119::YFP
expression. PCR analysis showed that the med-2 gene remained intact on irDp1.
In addition to unc-32 and med-1, irDp1 complements dpy-17, sDf127, and unc-
36, suggesting that it contains most of sDp3. To make MS162 [med-1; dpy-17
sDf127 unc-32; irDp1], med-1 males were crossed with lon-2; dpy-17 sDf127
unc-32; irDp1 hermaphrodites, and YFP(+) F2 descendants were identified that
segregated only dead eggs and viable non-Lon YFP(+) animals. Consistent with
their being of similar size, irDp1 and sDp3 are inherited by approximately 60%
of progeny (data not shown; Hedgecock and Herman, 1995).
To replace the sDf127 chromosome with med-2(cx9744), med-2 males were
crossed to med-1; dpy-17 ncl-1 unc-36 hermaphrodites, and progeny males were
then crossed to med-1; dpy-17 ncl-1 unc-36; irDp1. Wild-type F2 animals from
this cross were singled out and the line MS247 [med-1; med-2; irDp1] was one
of those that segregated only dead eggs and viable non-DpyUnc YFP(+)
animals. PCR analysis showed that MS247 is homozygous for med-1(ok804)
and med-2(cx9744). Construction of MS290, a strain derived from MS247 in
which irDp1 has been replaced by an array containing the med-1(+) plasmid
pMM277 and the unc-119::CFP reporter pMM809, is described in Coroian et al.
(2005). MS290 transmits the med-1(+) array to approximately 45% of progeny.
Genotypes were confirmed by PCR where appropriate. Additional strain
construction details are available on request.
Microscopy and imaging
An Olympus BX-71 microscope was used for fluorescence and Nomarski
microscopy. Images were captured using either a monochrome Microfire CCD
or a Canon EOS-350D digital SLR coupled to an LMscope DSLRC adapter
(Micro Tech Lab, Austria). GFP, YFP, and CFP were detected using appropriate
filter sets (Miller et al., 1999) obtained from Chroma Technology Corp. Images
were processed with Adobe Photoshop 7, and figures compiled with Adobe
Illustrator CS2.
In situ hybridization
Detection of mRNA in situ was performed as described, using antisense RNA
probes of size 0.5 kb–0.8 kb (Coroian et al., 2005). Freeze-crack permeabilized
embryos and hermaphrodites were treated with Streck Tissue Fixative (Streck,
Inc.) for 1–2 h at 37°C prior to hybridization. RNA probes were prepared using the
Roche DIG RNA labeling kit (#1 175 025) with PCR products tagged on one side
with the T7 RNA polymerase recognition sequence. All experiments were
performed a minimum of two times with three microscope slides in each
experiment. In any given experiment, probe quality and concentration were
assayed by staining wild-type animals fixed in parallel, and including only those
experiments in which strong staining, with minimal background, was observed in
these controls. Both antisense and sense med-1 probes frequently detected weak
signal in the anus and pharyngo-intestinal valve, but only antisense med probes
detect signal in the gonad, anterior intestine, and early embryo.
RNA interference
RNA interference for skn-1, pal-1, and pop-1 was performed by growing
animals on E. coli HT115 bacteria expressing dsRNA (Timmons et al., 2001).Results
SKN-1-dependent med expression occurs maternally and
zygotically
med-1 and med-2 translational reporter fusions display
expression that can be detected in the nuclei of EMS, its
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(Maduro et al., 2001). We performed RNA in situ hybridization
using an antisense med-1 probe, which detects both med-1 and
med-2 transcripts owing to their 98% sequence identity. We
confirmed that embryonic med transcripts do indeed accumulate
in the EMS nucleus at the 4-cell stage, become cytoplasmic in
MS and E, and are undetectable thereafter (Fig. 1A) (Coroian et
al., 2005). Signal was also observed in the gonads of all adults,
with 68% (174/257) showing very strong staining (Fig. 1A),
while very little or no gonadal signal was observed using sense
probes (not shown). In the related nematode, C. briggsae, we
also found that in situ hybridization with a Cb-med-1 probe
reveals gonadal as well as embryonic signal in EMS (Fig. 1H)
(Coroian et al., 2005). We did not detect significant levels of
med transcripts in very early embryos or late oocytes (data
not shown). We conclude that med expression has both aFig. 1. Detection of med and pal mRNAs by in situ hybridization. (A) Wild-type (N2
parallel experiments, expression is strongly abrogated in the gonads of skn-1(zu67) h
of zygotic med transcripts. (C) JM134 shows high levels of gonadal med signal sim
MS162 demonstrates strongly abrogated maternal expression, but zygotic overexpres
(in med-1(ok804) animals) shows both maternal and zygotic expression. (F) Detection
normal zygotic expression. (G) An extrachromosomal array providing rescue to a me
overexpression. (H) Maternal and zygotic activation of the meds is conserved in the
embryos at the 12-cell stage. In N2, pal-1 accumulates stronger signal than med-1 wh
pal-1 activation is seen in the sister cells C and P3. In the absence ofmed-1,2, an addit
transformation seen in med-1,2(RNAi) (Maduro et al., 2001). Embryos are shown wit
in panel A are 100 μm (adult image) and 10 μm (embryo image).maternal and zygotic component, and that both components are
evolutionarily conserved.
We compared maternal med expression with that of pal-1, a
gene that is also expressed both maternally and zygotically, and
which acts to specify the C and D lineages (Baugh et al., 2003;
Hunter and Kenyon, 1996). Gonadal signal detected under
similar conditions with a pal-1 probe suggests that maternal
med transcripts are significantly less abundant than those of
pal-1 (Fig. 1I). This observation is consistent with results
from global microarray experiments, which detected significant
germline signal for pal-1 mRNA but not for med-1 (Reinke et
al., 2004). Hence, maternal med transcripts are of relatively low
abundance.
The bZIP/homeodomain factor SKN-1 is required for
embryonic expression of med transgenes (Bowerman et al.,
1993; Maduro et al., 2001). Recombinant SKN-1 protein can) animals show gonadal signal and activation in EMS at the 4-cell stage. (B) In
ermaphrodites and in their progeny. skn-1(RNAi) embryos were similarly absent
ilar to wild-type. Embryos carrying sDp3 also express med-2 zygotically. (D)
sion, due to an integrated med-1(+) transgene on irDp1. (E) Detection of med-2
of med-1 (in med-2(cx9744) animals) shows decreased maternal expression, but
d-1(ok804); med-2(cx9744) strain demonstrates maternal expression and zygotic
related nematode C. briggsae. (I) Detection of pal-1 mRNA in the gonad and
en detected with a similar-sized probe (left panel). At the 12-cell stage, zygotic
ional expression component appears in MS and E, consistent with the MS, E→C
h the anterior to the left, and dorsal to the top in this and other figures. Scale bars
Table 1
Intestinal differentiation in mutant embryos
Genotype % Intestine a (n)
Wild type 100 (n>500)
med-1(ok804) 100 (240)
med-2(cx9744) 100 (774)
dpy-17(e164) sDf127 unc-32(e189) b 100 (196)
dpy-17(e164) sDf127 unc-32(e189) c 100 (127)
unc-32(e189) 100 (249)
med-1(ok804); dpy-17(e164) sDf127 unc-32(e189) b [JM134] 77 (121)
med-1(ok804); dpy-17(e164) sDf127 unc-32(e189) c [MS162] 49 (525)
med-1(ok804); med-2(cx9744) d [MS290] 83 (165)
med-1(ok804); med-2(cx9744) c [MS247] 53 (263)
skn-1(RNAi) 28 (731)
med-1(ok804); skn-1(RNAi) 33 (220)
med-2(cx9744); skn-1(RNAi) 21 (394)
med-1(ok804); med-2(cx9744); skn-1(RNAi) 11 (102)
end-1(ok558) 100 (322)
end-1(ox134) 100 (364)
end-3(ok1448) 95 (155)
med-1(ok804); dpy-11(e224) end-1(ok558) 100 (181)
med-1(ok804); end-3(ok1448) 42 (251)
med-2(cx9744); dpy-11(e224) end-1(ok558) 98 (344)
med-2(cx9744); end-3(ok1448) 97 (150)
med-1(ok804); dpy-17(e164) sDf127 unc-32(e189);
skn-1(RNAi) c
19 (68)
med-1(ok804); dpy-17(e164) sDf127 unc-32(e189);
dpy-11(e224) end-1(ok558) b
32 (207)
med-1(ok804); dpy-17(e164) sDf127 unc-32(e189);
dpy-11(e224) end-1(ok558) c
3 (123)
med-1(ok804); med-2(cx9744); dpy-11(e224) end-1(ok558) c 3 (121)
med-1(ok804); med-2(cx9744); end-3(ok1448) c 37 (258)
a Scored by presence of birefringent gut granules in terminal embryos.
b Segregated from mothers carrying sDp3, which provides maternal med(+)
activity.
c Segregated from mothers carrying irDp1, which causes knockdown of
maternal med transcripts.
d Segregated from mothers carrying irEx138, which provides maternal
med(+) activity.
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are required for med-1 reporter expression (Blackwell et al.,
1994; Maduro et al., 2001). To assess the requirement of SKN-1
for endogenous med activation, we performed in situ hybridiza-
tion to detect med transcripts in embryos and adults depleted for
skn-1 activity. In the progeny of skn-1(zu67) mothers, or of
animals fed skn-1 dsRNA-expressing bacteria, we failed to
detect embryonic med transcripts (Fig. 1B and data not shown).
Furthermore, while gonadal expression was detectable in skn-1
(zu67)/nT1 animals, the signal was almost undetectable in skn-1
(zu67) homozygotes (Fig. 1B). We conclude that SKN-1 is
required for both maternal and zygotic activation of the med
genes.
To determine whether med-1 and med-2 might be differen-
tially regulated, we performed in situ hybridization on strains
harboring a mutation in one gene but not the other. The mutation
ok804 deletes the entire med-1 locus (Coroian et al., 2005).
Staining of med-1(ok804), which should detect only med-2
transcripts, shows signal in the gonad and embryo that is
comparable to that seen in wild-type, with 67% (108/161) of
adults showing strong signal (Fig. 1E). The cx9744 mutation is
a Mos1 transposon insertion in the med-2 open reading frame
that is predicted to result in production of an aberrant mRNA
containing an early nonsense mutation (Coroian et al., 2005).
These aberrant transcripts would be expected to be rapidly
degraded by the Smg mRNA surveillance system (Pulak and
Anderson, 1993). Staining of the med-2(cx9744) strain, which
should therefore specifically detect only med-1mRNA, shows a
dramatic reduction in the gonad signal: only 15% (25/166) of
adults showed staining, and this staining was significantly
weaker than in wild-type or med-2(−) (Fig. 1F). We conclude
that while both med-1 and med-2 are activated to roughly
similar levels in the 4-cell embryo, med-2 produces more germ
line transcripts than med-1. Despite these differences, however,
homozygosity for either med allele does not result in an
endoderm defect (Table 1).
Maternal med activity rescues endoderm (E) but not mesoderm
(MS) specification
The original assessment of med loss-of-function was based
on knockdown of med expression by RNAi. Direct gonadal
injection of med-1 dsRNA (which targets both med-1 and med-
2) produces arrested progeny embryos, all of which lack
posterior pharynx and nearly all PAL-1-independent body wall
muscle, tissues normally made by descendants of MS (Maduro
et al., 2001; Sulston et al., 1983). Approximately 50% of these
embryos also lack differentiated endoderm. In contrast to these
results, Goszczynski and McGhee (2005) reported that 80–97%
of embryos chromosomally lacking med-1 and med-2 make
endoderm. One strain the authors used to produce med-1,2(−)
embryos, JM134, is homozygous for med-1(ok804) and
sDf127, a large deletion that removes many genes including
med-2 (Figs. 2A, B). The lethality of sDf127 in this strain is
complemented by the free duplication sDp3, which carries
med-2(+). We confirmed that while sDf127 embryos (derived
from an sDf127; sDp3 mother) made endoderm 100% of thetime (n=196), 77% of med-1; sDf127 embryos (n=121)
segregated by med-1; sDf127; sDp3 mothers (strain JM134)
made endoderm (Figs. 3A, B and Table 1).
As RNAi can efficiently target maternal as well as zygotic
transcripts (Fire et al., 1998), the simplest explanation for the
lower percentage of gutless embryos from the JM134 strain
compared to that obtained by med-1,2(RNAi) experiments is
that maternal med expression can rescue endoderm. We
performed in situ hybridization on JM134 and found that this
strain accumulates med transcripts in the gonad similar to wild-
type animals, with 75% (57/76) of adults showing strong
gonadal staining (Fig. 1C). Hence, the JM134 strain demon-
strates maternal med-2 expression from sDp3.
The presence of gonadal med transcripts in the JM134 strain,
whose med-1,2(−) progeny demonstrate a weaker endoderm
phenotype than med-1,2(RNAi), suggests that endoderm
specification in med-1,2(−) embryos can be partially rescued
by maternal med transcripts. We tested this hypothesis by
assessing endoderm specification in med-1,2(−) embryos
produced by mothers that lack gonadal med transcripts. To
deplete maternal med expression reliably, we modified sDp3 to
contain an integrated med-1(+) array, generating the free
Fig. 2. Genotypes of med strains used to test maternal and zygotic med function. (A) Gene arrangement of part of LGIII containing med-2. sDf127 is a ∼1 MB
deletion that removes ∼240 genes including med-2 (http://www.wormbase.org, release WS160). sDp3 is a free duplication that complements sDf127, dpy-17, and a
large portion of LGIII to the left (not shown). irDp1 is sDp3 carrying an unmapped integrated array containing med-1(+), unc-32(+) and unc-119::YFP (see Materials
and methods). The med-1(+) array causes germline cosuppression of med-2 on irDp1. (B) Production of chromosomally med-1,2(−) embryos in JM134 (Goszczynski
and McGhee, 2005) and in MS162, in which sDp3 has been replaced by irDp1. While the JM134 strain has the Unc32 phenotype, MS162 animals are essentially wild-
type. (C) Production of med-1,2(−) embryos to test maternal contribution of either med gene. Expected genotype ratios are shown. Abbreviations: m+z−, maternal
product supplied, zygotic product absent; m−z−, maternal and zygotic products absent.
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predicted to cause depletion of maternal med transcripts by
transgene-mediated cosuppression (Dernburg et al., 2000;
Robert et al., 2005). The resultant strain, MS162, has the
same genotype as JM134 (i.e. med-1; sDf127) but is balanced
by irDp1 instead of sDp3. We performed in situ hybridization
on MS162 and found that gonadal med transcripts were
undetectable in 99% (69/70) of adults, while embryonic levels
were greatly enhanced in EMS (Fig. 1D). This enhanced
expression is consistent with zygotic expression of the repetitive
med-1(+) transgene, as a chromosomally integrated med-1::
GFP::MED-1 strain produced a similarly strong EMS signalwhen stained with an antisense GFP probe (data not shown). We
conclude that transgene cosuppression can be used to abrogate
endogenous maternal med-2 transcript accumulation, and that
this cosuppression does not prevent zygotic activation.
If maternal med expression can rescue endoderm specifica-
tion in some med-1,2(−) embryos derived from JM134 mothers,
then med-1,2(−) embryos produced by MS162, which lacks
germline med transcripts, would be predicted to make endoderm
less frequently. Indeed, 51% of the med-1,2(−) embryos
produced by MS162 lack endoderm (Fig. 3C, Table 1), similar
to the results we obtained using RNAi (Maduro et al., 2001). To
rule out any chromosomal differences between JM134 and
Fig. 3. Gut granules inmedmutant embryos. (A) All embryos homozygous for a
deletion that removesmed-2make gut as seen by the similar-sized regions of gut
granule birefringence. (B) JM134 generatesmed-1; sDf127 embryos that contain
varying degrees of gut. (C)MS162 generates genetically identicalmed-1; sDf127
embryos, but fewer of these make endoderm. Fields are approximately 0.5 mm
across.
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progeny males back to JM134 repeatedly. We obtained similar
results (∼50% endoderm defect among med-1,2(−) embryos)
after 3× and 10× backcrosses, confirming that the increased
severity of the endoderm defect is linked to irDp1, and is not
due to a fortuitous background mutation. Replacement of the
sDf127 chromosome in MS162 with med-2(cx9744), to create
strain MS247, also resulted in a similarly strong endoderm
defect (Table 1), showing that the increased endoderm defect
with irDp1 does not require the loss of other genes deleted by
sDf127. We conclude that maternal med-2 expression on
sDp3 can rescue endoderm specification in a significant fraction
of med-1,2(−) embryos.
To rule out any contribution of the additional genes on the
sDp3 or irDp1 balancers used to propagate the med-1; med-2
strains, we replaced irDp1 with an extrachromosomal array
containing only med-1(+) and unc-119::CFP, to create
MS290 (med-1(ok804); med-2(cx9744); Ex[med-1(+)]) (Cor-
oian et al., 2005). As the vast majority of arrays in C. elegans
do not show germline expression (Kelly et al., 1997), med-
1,2(−) embryos produced by MS290 would not be expected
to be maternally rescued for endoderm specification. Unex-
pectedly, med-1,2(−) embryos segregated from this strain
made endoderm 83% (137/165) of the time, suggesting that
they were maternally rescued. When we performed med in
situ hybridization on MS290, we detected very high levels of
gonadal med transcripts (Fig. 1G). This suggests that intrinsic
differences between the med-1(+) array on irDp1 and the
extrachromosomal med-1(+) array in MS290 preclude germ-
line transcript accumulation in one case but not the other.
Nonetheless, these results provide a further correlationbetween the presence of germline med transcripts in a mother
animal and an increased likelihood that its med-1,2(−)
progeny will make endoderm.
As the MS blastomere is also specified by the activity of the
meds, we assayed for maternal rescue of the MS defect in med-1
(ok804); med-2(cx9744) embryos. As anticipated by our prior
RNAi results, all med-1,2(−) embryos from a mother carrying
irDp1 arrest without MS-derived posterior pharynx, as scored
both by Nomarski optics and expression of the pharynx muscle
marker ceh-22::GFP (Coroian et al., 2005; Okkema and Fire,
1994; data not shown). We then examined med-1,2(−) embryos
made by MS290 mothers, which provide maternal med(+)
activity, and found that 100% of the med-1,2(−) embryos lacked
posterior pharynx. Hence, maternal med transcripts produced
by a med-1 transgene array cannot rescue MS fate in
med-1,2(−) embryos.
To provide a maternal source of med expression from a
normal chromosomal context, we constructed animals homo-
zygous for a mutation in one med gene and heterozygous for a
mutation in the other, such that 1/4 of the self-progeny are
expected to be med-1,2(−) (Fig. 2C). We found that 26% (190/
528) of the progeny of med-1/+; med-2 mothers arrested,
consistent with expected Mendelian segregation (p=0.4) and
lethality of the med-1; med-2 genotype. However, 42% (332/
783; p<10−6 compared with expected 1:3) of the progeny of
med-1; med-2/+ mothers arrested as embryos. As med-1; +/+
embryos are almost always viable, we compute that approxi-
mately 35% of med-1; med-2/+ embryos undergo embryonic
arrest due to zygotic haploinsufficiency of med-2 in the absence
of med-1. All arrested embryos made from either med-1/+;
med-2 mothers or med-1; med-2/+ mothers lacked posterior
pharynx as scored by Nomarski optics, confirming that MS fate
cannot be rescued by a maternal med(+) gene in its normal
chromosomal context. The arrest of 35% of med-1; med-2/+
embryos further suggests that a single zygotic copy of med-2
cannot always rescue MS fate.
We also evaluated rescue of E specification by a single
maternal dose of med-1 or med-2. 31% (59/190) of the arrested
progeny from med-1/+; med-2 mothers lacked endoderm,
while 13% (42/332) of the arrested progeny from med-1; med-
2/+ mothers lacked endoderm. Given that 1/4 of the progeny in
this latter case are expected to be of the med-1; med-2
genotype, we calculate that a maximum of 21% (42/196) of
these lacked endoderm. The 31% [maternal med-1(+)] and
21% [maternal med-2(+)] gutless phenotypes contrast sharply
with the ~50% of med-1,2(−) embryos that lack endoderm
when germline med transcripts are reduced by transgene
cosuppression or RNAi. We conclude that a single chromoso-
mal copy of either med-1 or med-2 can maternally rescue
specification of E, but not MS, in med-1,2(−) embryos. That
more med-1,2(−) embryos are rescued when the mother carries
med-2(+) is consistent with the observation that med-2
accumulates more gonadal transcripts than med-1. The
differences in gonadal expression and maternal rescue of
endoderm suggest that despite 98% sequence identity between
the med genes, there are qualitative differences in their
contributions to embryonic development.
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gonad
As an alternate approach to preventing med transcripts
from being transmitted via the maternal gonad, we obtained
med-1,2(−) embryos from mosaic animals that carry med-1(+)
gene in the soma, but have a med-1(−) germline. For the strain
MS290 (med-1(ok804); med-2(cx9744); Ex[med-1(+)]), such
mothers can be recognized because they give rise to a brood
consisting entirely of arrested embryos instead of an approx-
imate 1:1 distribution of viable:arrested embryos. From 280
singled MS290 mothers, we obtained 8 (3%) germline mosaics
and found, somewhat unexpectedly, that 73% of their progeny
(n=195) contained endoderm. A similar result (73% endoderm,
n=125) was also seen with the progeny from a single germline
mosaic med-1(ok804); med-2(cx9744); sDp3 mother. Hence,
there is at most only a slight reduction in the degree of maternal
med rescue of endoderm when the maternal germline lacks a
med(+) gene, rather than a reduction to ∼50% as seen with
RNAi or when transgene cosuppression is used to abrogate
gonadal med transcripts.
One possible explanation for this discrepancy is that somatic
med transcripts are imported into the gonad from another tissue.
Indeed, we observed that 80% of wild-type adults (n=45)
stained with med-1 antisense probe demonstrated strong
expression in the anterior intestine (data not shown). In
contrast, only 29% of skn-1(RNAi) animals (n=42) demon-
strated qualitatively similar staining, though at a lower level.
In controls using antisense probes for other genes (myo-3,
myo-2, and hlh-1), we observed only weak anterior intestine
expression in less than 10% of animals (n>70 for each case).
These results suggest that the SKN-1-dependent transcripts
found in the adult gonad may result from somatic transcrip-
tion. This result is further supported by the finding that SKN-1
protein, which activates med expression in the EMS cell, is
also present in the intestine (Bowerman et al., 1993).
med-1 and med-2 are essential for normal E development
The foregoing experiments and our previously published
studies have established that while all med-1,2(−) embryos lack
cell types made by the MS blastomere, a significantly large
proportion of such embryos still make endoderm. As an
epitope-tagged med-1::c-myc::MED-1 transgene reveals trans-
genic MED-1 protein in only the EMS, MS and E nuclei
(Maduro et al., 2001), we wished to investigate whether there
might be a role for the meds beyond specification of an
endodermal fate.
There is evidence that some med-1,2(RNAi) embryos that
make endoderm show defects in early E development. In wild-
type embryos, the E daughter cells Ea and Ep migrate into the
interior of the embryo at the onset of gastrulation (Sulston et al.,
1983). In some med-1,2(−) embryos, Ea and Ep divide
precociously on the ventral surface (Maduro et al., 2001).
Similar defects are also seen in skn-1(zu67) mutant embryos,
consistent with the participation of skn-1 and the meds in the
same genetic pathway (Bowerman et al., 1992; Maduro et al.,2001). When endoderm is not made in med-1,2(−) embryos, the
E cell (as with MS in all med-1,2(−) embryos) adopts the fate of
its lineal cousin, the mesectodermal precursor C (Maduro et al.,
2001). Specification of C and the ectopic C-like cells made in
med-1,2(−) embryos requires maternal activity of the Caudal-
like homeodomain protein PAL-1 (Hunter and Kenyon, 1996).
In the normal C cell, maternal PAL-1 activates zygotic
expression of pal-1, providing an early marker for specification
of this lineage (Baugh et al., 2005).
To test for activation of zygotic pal-1 in med-1,2(−)
embryos, we performed pal-1 in situ hybridization on wild-
type embryos and those from the MS247 [med-1; med-2; irDp1]
strain. pal-1 mRNAwas detected in C and P3 in 87% (26/30) of
wild-type embryos showing staining (Fig. 1I), and at low levels
in C, P3, MS, and E in the remaining 13%. This suggests that
PAL-1 can activate a low level of zygotic pal-1 in a small
proportion of MS and E cells. In contrast, 47% (14/30) of stained
MS247 progeny showed expression in C and P3, and the
remaining 53% showed staining in C, P3, MS, and E (Fig. 1I). As
the frequency of meiotic loss of irDp1 is approximately 40%, this
suggests that the majority of, if not all, med-1,2(−) embryos
activate pal-1 in MS and E. We also observed similar ectopic
expression of a zygotic pal-1::YFP reporter in med-1,2(−)
embryos, suggesting that these pal-1 transcripts do not represent
perdurance of maternal message (data not shown). Therefore,
many (if not all) of the E cells that ultimately produce gut in
med-1,2(−) embryos contain aberrant pal-1 transcripts.
We hypothesized that division and expression defects in the
early E lineage may manifest themselves in later embryonic
development by altering the pattern of cell divisions in the E
lineage. The E cell normally divides 4–5 times to produce 20
cells by the end of embryogenesis (Sulston et al., 1983).
Terminal sDf127 embryos contain a patch of gut granules that
comprises ∼25% of the cross-sectional area of the embryo, and
which can be seen to be fairly consistent from embryo to
embryo (Fig. 3A). In contrast, many med-1; sDf127 embryos
contain gut granule patches that occupy as little as 10% of the
area, or consist of only a small number of puncta (Fig. 3B). We
asked whether this reflects a change in the number of gut cells
by examining the endoderm in various med-1,2(−) strains using
a chromosomally integrated elt-2 reporter transgene to mark
intestinal nuclei, as has been used in similar studies of gut cell
number (Fukushige et al., 1998; Kostic et al., 2003). A
summary of our results is shown in Fig. 4. As expected, wild-
type and single med-1 or med-2 embryos made an average of 20
elt-2-expressing cells with little variation. We found that
sDf127 embryos make endoderm with a similar mean number
of cells as wild-type, although with a slightly higher variance.
The variation was similar in embryos segregated from mothers
carrying sDp3 or irDp1, suggesting that the increased variance
compared to that in med-2(−) embryos results from loss of other
gene(s) in sDf127, rather than from differences in the two free
duplications.
Among med-1,2(−) embryos that still made endoderm, the
average number of gut cells was reduced, and the variance
increased significantly. med-1; sDf127 embryos segregated
from mothers carrying either sDp3 or irDp1 showed a combined
Fig. 4. Number of endoderm cells in late-stage embryos. (A) Distribution of gut cell numbers among embryos making endoderm. A small pie chart indicates the
proportion of embryos of the given genotype that make endoderm (darker portion) as shown in Table 1. The histograms represent the numbers of embryos containing
the number of gut cells indicated along the X axis. The height of the bars has been normalized to that of the modal class within each genotype. Mean±SEM and total
embryos scored (n) are shown towards the right. (B) Examples of appearance of elt-2::GFP-expressing cells among 3× or terminal embryos. Multiple epifluorescence
images at different focal planes were digitally stacked.
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1.0 cells, respectively. The majority of embryos contained less
than 20 cells (67% in the case of sDp3(+) mothers, and 55% for
irDp1). med-1,2(−) embryos segregated from irDp1(+)mothers
showed a lower mean number (12.0±0.8) and an even higher
proportion (81%) of embryos with subnormal numbers of gut
cells. We found, overall, that only 10% of med-1,2(−) embryos
with any endoderm contain a normal number of 20 gut cells.
Thus, 93–95% of med-1,2(−) embryos either make no gut or
make a gut that contains abnormal numbers of cells. We
conclude, therefore, that med-1 and med-2 are important for
normal development of the endoderm in the vast majority of
C. elegans embryos.Distinguishable contributions of end-1 vs. end-3
The paralogous end-1 and end-3 genes appear to function
redundantly (Maduro et al., 2005a). Loss of med-1, med-2, or
end-1 individually has no detectable endoderm phenotype,
while loss of end-3 results in a weak endoderm specification
defect, with approximately 5% of end-3(−) embryos failing to
make gut (Table 1). We tested the ability of mutations in end-1
or end-3 to enhance mutations in themeds (Table 1).med-1,2(−)
embryos lacking the maternal contribution were greatly
enhanced for gutlessness by end-1 (only 3% made gut) but not
end-3 (37% made gut). In combinations of med and end single
mutants, three of the four possible med; end double mutants
Fig. 6. Expression of the ends in mutant backgrounds. (A) In skn-1(RNAi)
embryos, end-3 mRNA is not detected. (B). end-3 is derepressed in the MS cell
in pop-1(RNAi). A single additional embryo (not shown) had expression in only
the E cell. (C) end-1 mRNA is still detected in skn-1(RNAi). (D) In end-3
(ok1448) mutant embryos, end-1 mRNA levels are reduced. (E) Depletion of
pop-1 by RNAi results in derepression of endogenous end-1 mRNA in the
MS lineage. An additional seven embryos showed signal in Ea/Ep alone. (F)
end-3(ok1448); pop-1(RNAi) embryos show no detectable end-1 mRNA
above background levels. Percentages and numbers shown are as in Fig. 5.
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The med-1; end-3 double mutant, however, showed strong
synergy, as only 42% of embryos made gut. Among those that
made endoderm, the number of gut cells made was nearly always
abnormal (Fig. 4). These results show that end-1 and end-3
make different contributions to endoderm specification.
Global transcriptome analysis has suggested that end-3 is
activated slightly earlier than end-1 (Baugh et al., 2003). We
performed in situ hybridization to detect end transcripts in
wild-type embryos. end-3 mRNA was detected in 84% of
embryos at the 1E stage, 63% of 2E stage embryos, and 0% of
4E stage embryos (Figs. 5A, C, E). end-1 transcripts, by
contrast, were detected in 19% of 1E, 90% of 2E, and 83% of
4E stage embryos (Figs. 5B, D, F). These differences confirm
an earlier onset of end-3 activation as compared with end-1.
We note that, for both end-1 and end-3 in situ hybridization at
the 2E stage, approximately half of the stained embryos
showed stronger signal in Ep than in Ea (Figs. 5C, D;
discussed below).
We next tested for end activation differences in the absence
of the SKN-1→MED-1,2 pathway by depleting skn-1, a
treatment that results in abrogation of both skn-1 and the meds
(this work and Maduro et al., 2001). In skn-1(RNAi) embryos
end-3 mRNA is undetectable, while end-1 is still expressed
at high levels (Figs. 6A, C). We conclude that the early
activation of end-3 is accomplished primarily by the activity of
SKN-1→MED-1,2, while end-1 is still activated in their
absence.Fig. 5. end-3 is activated earlier than end-1. Detection of transcripts by in situ
hybridization is shown for end-3 at the 1E (A), 2E (C), and 4E (E) stages, and
end-1 at similar stages in panels B, D, and F respectively. Percentages shown
indicate the proportion of embryos of a given stage that showed expression, with
total number scored in brackets. Note that in panels C and D, signal is stronger in
Ep than in Ea. This was observed in approximately 50% of embryos;
symmetrical signal was observed in the remainder. Slides for each probe were
prepared from the same batch of embryos.END-3 and POP-1 activate end-1
Previous experiments established that while the primary role
of POP-1 in endoderm specification is the repression of
endoderm fate in the MS cell, it also contributes to Wnt-
dependent activation of the endoderm specification pathway in
the E cell (Lin et al., 1995; Maduro et al., 2002, 2005b; Shetty et
al., 2005). Consistent with this observation, in the absence of
end-3, specification of the endoderm becomes largely depen-
dent on POP-1 (Maduro et al., 2005b). We examined expression
of the ends in a pop-1(RNAi) background, and found that
transcripts for both genes become detectable to equal levels in
the MS and E lineages in a manner that recapitulates their
temporal differences in wild-type (Figs. 6B, E). A repressive
role for POP-1 in the Ea cell also became apparent, as >90% of
2E stage pop-1(RNAi) embryos showed equal levels of end-1
expression in Ea and Ep (visible in Fig. 6E). We have previously
shown that transgenic GFP::POP-1 can interact directly with the
end-1 and end-3 promoters in vivo at the 2E stage (Maduro
et al., 2002). We conclude that end-1,3 are still responsive to
POP-1 in the E daughter cells.
Given the observation that end-3 mRNA accumulates in E
earlier than end-1 mRNA, and that an end-3; pop-1 double
mutant shows a synergistic defect (only 3% make gut), we
hypothesized that END-3 might activate end-1 in parallel with
POP-1. There is likely sufficient time for active END-3 to be
synthesized from the end-3 mRNA before the E cell divides, as
the product of an end-3::c-myc::END-3 fusion transgene can be
detected near the end of the E cell cycle (MM and JR,
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mRNA is detectable, though at lower levels than in the wild
type (Fig. 6D). In end-3(ok1448); pop-1(RNAi) embryos,
however, expression of end-1 becomes essentially undetectable
(Fig. 5F). We conclude that both POP-1 and END-3 together are
essential activators of end-1.
Discussion
A complex network specifies C. elegans endoderm
The advances we have made in this study are as follows: (1)
The med genes are expressed maternally in both C. elegans and
C. briggsae; (2) Like the zygotic activation of med-1,2,
maternal expression requires SKN-1; (3) Endoderm (E) but
not mesoderm (MS) fate is partially rescued by this maternal
activity; (4) When specification of endoderm is partially
compromised, abnormal numbers of intestinal cells are made;
(5) med-1 and med-2 make different genetic contributions to E
specification, as do end-1 and end-3; (6) end-3 is activated
earlier in the E cell cycle than end-1; (7) In addition to acting in
parallel with end-1 in promoting endoderm fate, END-3 also
activates end-1. Our data reveal new and unexpected complexi-
ties in the C. elegans endoderm gene cascade (Fig. 7).
Maternal deployment of the embryonic SKN-1→MED-1,2
pathway
We have previously shown that maternally supplied SKN-1
directly activates med-1,2 transgenes in the early EMS lineage,
placing med-1,2 downstream of maternal SKN-1. We have
shown here that a significant amount of med mRNA accu-
mulates in the hermaphrodite germline, and that this componentFig. 7. A comprehensive model for C. elegans endoderm specification. Arrows
indicate direction of positive regulation as follows: solid arrows indicate our
subjective assessment of the strongest regulatory interactions in wild-type
embryos, while dashed arrows indicate weaker contributions. All arrows shown
have been substantiated by genetic interactions presented in this and other work
(Bei et al., 2002; Maduro et al., 2001, 2005b; Rocheleau et al., 1997, 1999;
Thorpe et al., 1997; Zhu et al., 1998).of med expression also requires SKN-1. Although the med
genes are 98% identical within their intronless coding regions
and in several hundred base pairs of flanking genomic DNA
(Maduro et al., 2001), suggesting they are regulated by similar
mechanisms, higher levels of maternal med-2 mRNA were
detected than for med-1. As med-1 is X-linked, and the X
chromosome is specifically underrepresented for genes
expressed in the maternal germline (Reinke et al., 2000), a
global X chromosome repression mechanism may act to down-
regulate maternal med-1 transcription.
We were unable to detect med transcripts above background
levels in the very early embryo, even though transcripts for
other maternal genes such as skn-1 are detectable this early
(Seydoux and Fire, 1994). One possibility is that a low level of
med transcripts in early embryos is simply beyond our ability to
detect beyond background signal. Alternatively, some post-
transcriptional contribution, such as MED protein, or even end-
1,3mRNA, might be deposited into oocytes. We have seen very
weak evidence for a maternal contribution of end-3: 98% of
end-3(zu247) embryos (n=689) derived from an end-3
(zu247)/+ mother made endoderm, while end-3(zu247)
embryos from an end-3(zu247) mother made endoderm
approximately 94% of the time (n=518, p<0.001; MM and
JR, unpublished). Regardless of the mechanism, we have shown
genetically that the maternal med component is capable of
rescuing E specification, but not MS specification, in a fraction
of med-1,2(-) progeny embryos.
We have further shown that accumulation of germline
transcripts requires SKN-1 function in the mother. As
regulation of the meds by SKN-1 is direct in the embryo,
maternal activation of the meds is also likely to be direct.
While SKN-1 protein has been detected in early embryos, it
was not detected in the adult gonad (Bowerman et al., 1993).
This may be because it is below threshold levels for detection.
However, our germline mosaic and in situ hybridization data
suggest that maternal transcription of the meds may take place
outside the germline, perhaps in the intestine, where SKN-1 is
also found (Bowerman et al., 1993). An intriguing model,
then, is that SKN-1 in the soma activates med expression, and
these transcripts are somehow transported into the maternal
gonad.
What is the purpose of deploying the SKN-1→MED-1,2
pathway maternally, before it is used embryonically? The
activity is clearly weak, as maternal med expression cannot
rescue mesoderm specification in the absence of embryonic
expression. The pathway that specifies the E fate must be
deployed on a relatively short time scale, approximately 20 min
(Baugh et al., 2003). It is possible, therefore, that maternal med
activation primes the endoderm specification pathway. Our
genetic data show that med activity is particularly critical for
activation of end-3, which precedes that of end-1. As end-3
contains four MED binding sites, compared to only two in
end-1, end-3 might be more responsive to MED-1,2. Hence,
low levels of MED-1,2 in the very early embryo could bind the
end-3 promoter and set the stage for activation after E is born.
Accumulation of med transcripts in the germline requires
that mechanisms exist to prevent specification of endoderm fate
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the KH-domain proteins MEX-3 and GLD-1 plays a role in
blocking somatic differentiation in the germline (Ciosk et al.,
2006). In that study, a small number of germ cells acquired an
endoderm fate in mex-1; gld-1 mutants. During the oocyte to
embryo transition, the CCCH-type zinc finger OMA-1 is
required for oocyte maturation and the blockage of inappropri-
ate activation of cell specification pathways (Shirayama et al.,
2006). It is likely therefore, that multiple mechanisms act to
prevent inappropriate specification of endoderm in the
germline.
Splitting a redundant gene pair: a new function for END-3
Previous studies indicated that end-3 acts in parallel with
end-1 to promote endoderm specification (Maduro et al.,
2005a; Zhu et al., 1997). Null mutations of end-1 showed no
endoderm phenotype, while those for end-3 showed a weak
defect, suggesting that END-3 makes a stronger contribution to
endoderm specification (Maduro et al., 2005a). Here, we have
shown that activation of end-3 is more dependent on the SKN-
1→MED-1,2 pathway than is end-1. Furthermore, we have
confirmed earlier findings by others suggesting that end-3 is
activated earlier in the E cell cycle than end-1 (Baugh et al.,
2003), and found that end-1 expression is diminished in end-3
(−) embryos and essentially eliminated in end-3(−); pop-1(−)
embryos, demonstrating a requirement for both POP-1 and
END-3 in end-1 activation. Hence, end-3 mutants show a
weak endoderm defect, and end-1 mutants none, because loss
of end-3 also affects end-1. It will be of interest to see whether
any of these aspects of endoderm specification have been
conserved in C. briggsae, which also expresses maternal meds
(this work), and which encodes three end-like genes (Maduro
et al., 2005a).
E specification is coupled to the endoderm lineage
We have found that the genes that act to specify the E fate are
also important for production of the correct number of gut cells.
Mutations in the cell cycle regulators cki-1 and cdc-25.1 result
in supernumerary intestinal cells despite correct E specification
(Fukuyama et al., 2003; Kostic and Roy, 2002), suggesting that
improper activation of cell cycle regulators accounts for the
abnormal gut cell numbers we have observed in embryos that
make gut in endoderm-specification mutant backgrounds. It has
been proposed that specification of endoderm results from
activation of the genes elt-2 and elt-7, which then maintain their
expression by positive autoregulation (Fukushige et al., 1998;
Maduro and Rothman, 2002). The wee1 kinase homolog wee-
1.1, activated in the E cell, is an apparent target of MED-1,2
(Broitman-Maduro et al., 2005; Wilson et al., 1999), and
depletion of the ends by RNAi abrogates the expression of
intestinal genes (Pauli et al., 2006). There must therefore be
additional roles for the meds and ends in endoderm develop-
ment in addition to the activation of elt-2,7, or else subtle
defects in activation of elt-2,7 may persist into later stages.
Whatever the mechanism, correct deployment of the endodermgene cascade is required for both E specification and normal
development of the intestine, suggesting that E specification is
not an all-or-none event.
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